MedCity News March 14, 2025
MeiraGTx’s gene therapy for Parkinson’s disease will enter Phase 3 testing under a new joint venture the biotech is forming with Hologen, a generative AI startup. The joint venture has up to $230 million in committed capital; MeiraGTx gets additional cash for its pipeline.
MeiraGTx has one gene therapy in a potentially pivotal clinical trial for cancer patients and another gene therapy ready to start Phase 3 in Parkinson’s disease. Completing the studies will be expensive and raising money is challenging with stock market volatility increasing by the day. MeiraGTx found another way to fund both studies. It’s teaming up with an artificial intelligence startup to form a joint venture responsible for the Parkinson’s program, supported by up to $230...
Today's Sponsors
Today's Sponsor